Linezolid is the most cost effective treatment

Onlypunjab.com
US patient subgroup results from largest MRSA cSSTI study demonstrate better cure rates and lower healthcare costs for patients treated with ZYVOX. Treatment with ZYVOX� (linezolid injection, tablets and for oral suspension) for complicated skin and soft tissue infections (cSSTIs) caused by suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) resulted in higher cure rates and decreased healthcare costs compared with intravenous (IV) vancomycin, according to a U.S. sub-analysis of data presented today at the annual meeting of the Infectious Diseases Society of America (IDSA). These data, analyzed from the largest MRSA cSSTI study to date, demonstrated significantly better cure rates and costs savings of approximately $1,000 per patient when compared with vancomycin in the MRSA population. ZYVOX is the only oral therapy approved by the U.S. Food and Drug Administration for complicated skin and soft tissue infections (cSSTIs) caused by MRSA and is available in interchangeable IV and oral formulations.